Search Results - "Gerike, Torsten"

FREEDOM: A phase 3b efficacy and safety study of fedratinib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib by Verstovsek, Srdan, Harrison, Claire N., Barosi, Giovanni, Kiladjian, Jean-Jacques, Buglio, Daniela, Chia, Vincent, Gerike, Torsten, Jessent-Ciaravino, Valerie, Mostillo, Joseph, Zhang, Jun, Mesa, Ruben A.

“…Abstract only TPS7072 Background: Myelofibrosis (MF) is a serious life-threatening condition characterized by splenomegaly, constitutional symptoms, and…”
Get full text

A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence by Mesa, Ruben A., Barosi, Giovanni, Harrison, Claire N., Kiladjian, Jean-Jacques, Gale, Robert Peter, Laadem, Abderrahmane, Gerike, Torsten, Linde, Peter G., Sherman, Matthew L., Pariseau, Joseph, Verstovsek, Srdan

“…Abstract only…”
Get full text

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study by Gerds, Aaron T., Vannucchi, Alessandro M., Passamonti, Francesco, Kremyanskaya, Marina, Gotlib, Jason, Palmer, Jeanne M., McCaul, Kelly, Ribrag, Vincent, Mead, Adam J., Harrison, Claire, Mesa, Ruben, Kiladjian, Jean-Jacques, Barosi, Giovanni, Gerike, Torsten G., Shetty, Jeevan K., Pariseau, Joseph, Miranda, Gabriel, Schwickart, Martin, Giuseppi, Ana Carolina, Zhang, Jennie, Backstrom, Jay T., Verstovsek, Srdan

“…Introduction: MF is a clonal stem cell disorder characterized by progressive bone marrow failure, extramedullary hematopoiesis, and debilitating constitutional…”
Get full text

Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study by Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M, Kiladjian, Jean-Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Gerike, Torsten, Rose, Shelonitda, Li, Mingyu, Brownstein, Carrie, Mesa, Ruben A.

“…Abstract only 7057 Background: MF is a life-threatening MPN for which RUX is the only approved treatment (Tx) option. Patients (pts) who are…”
Get full text

A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT) by Silverman, Lewis R., Dohner, Hartmut, Dombret, Herve, Mufti, Ghulam J., Stone, Richard M., Rose, Shelonitda, Gerike, Torsten, Camus, Frederic, Fenaux, Pierre

“…Abstract only TPS7074 Background: Hypomethylating agents (HMAs) induce hematologic response in ~ 50% of higher-risk MDS pts; however, there are few treatment…”
Get full text

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia by Gerds, Aaron T., Vannucchi, Alessandro M., Passamonti, Francesco, Kremyanskaya, Marina, Gotlib, Jason R., Palmer, Jeanne M., McCaul, Kelly, Ribrag, Vincent, Mead, Adam J., Harrison, Claire N, Mesa, Ruben A, Kiladjian, Jean-Jacques, Barosi, Giovanni, Gale, Robert Peter, Laadem, Abderrahmane, Pariseau, Joseph, Gerike, Torsten, Zhang, Jennie, Linde, Peter G., Reynolds, Joseph G., Verstovsek, Srdan

“…Introduction: Approximately two-thirds of patients with primary or post-essential thrombocythemia/polycythemia vera myelofibrosis (MF) have anemia, many of…”
Get full text

Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts by Harrison, Claire, Schaap, Nicolaas, Vannucchi, Alessandro, Kiladjian, Jean-Jacques, Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Gerike, Torsten, Rose, Shelonitda, Zhang, Jun, Berry, Tymara, Brownstein, Carrie, Mesa, Ruben

Get full text

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study by Harrison, Claire, Schaap, Nicolaas, Vannucchi, Alessandro, Kiladjian, Jean-Jacques, Jourdan, Eric, Silver, Richard, Schouten, Harry, Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Gerike, Torsten, Rose, Shelonitda, Li, Mingyu, Berry, Tymara, Brownstein, Carrie, Mesa, Ruben

Get full text

Modelling of chemotherapy: the effective dose approach by Hasenclever, D, Brosteanu, O, Gerike, T, Loeffler, M

“…We sketch the development of the effective dose approach which provides a theoretical framework to interpret chemotherapy outcome data. Building on the…”
Get full text